RxSight, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 6, 2023
ALISO VIEJO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and fiscal year 2022 after the market close on Monday, March 6, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applications are downloaded and installed. Instructions are provided (including a dial-in option).
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high quality of vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Shelley B. Thunen
Chief Financial Officer
Investor Relations Contact: